Siponimod (Mayzent) has been TGA approved for the treatment of adults with secondary progressive multiple sclerosis (SPMS). The TGA approval is based on the results of the EXPAND study which found siponimod reduced the risk of disability progression. The study, published in The Lancet last year, found siponimod reduced the number of confirmed disability progression ...
Siponimod gets TGA tick for SPMS
By Mardi Chapman
27 Nov 2019